Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

S3319

Sigma-Aldrich

sPLA2 inhibitor

Synonym(s):

5-(4-Benzyloxyphenyl)-4S-(7-phenylheptanoylamino)pentanoic acid, KH064

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C31H37NO4
CAS Number:
Molecular Weight:
487.63
MDL number:
UNSPSC Code:
41106300
PubChem Substance ID:

assay

≥97.5% (HPLC)

form

powder

storage condition

under inert gas

color

white

mp

133-135 °C

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

SMILES string

OC(=O)CC[C@@H](Cc1ccc(OCc2ccccc2)cc1)NC(=O)CCCCCCc3ccccc3

InChI

1S/C31H37NO4/c33-30(16-10-2-1-5-11-25-12-6-3-7-13-25)32-28(19-22-31(34)35)23-26-17-20-29(21-18-26)36-24-27-14-8-4-9-15-27/h3-4,6-9,12-15,17-18,20-21,28H,1-2,5,10-11,16,19,22-24H2,(H,32,33)(H,34,35)/t28-/m0/s1

InChI key

KWLUIYFCMHKLKY-NDEPHWFRSA-N

Application

sPLA2 inhibitor has been used in:
  • human lung adenocarcinoma cells in matrigel invasion assay
  • pre-treatment of cultured oligodendrocytes
  • the inhibition of secretory phospholipase A2 in lung adenocarcinoma.

sPLA2 inhibitor was used to study the effects on cell proliferation and apoptosis of lung cancer cells and oligodendrocytes.

Biochem/physiol Actions

Secretory phospholipase A2 inhibitor blocks the activation of NF-κB, Akt, p38 MAPK and ERK pathways. It reduces proliferation and induces apoptosis of lung cancer cells and is a potent anti-inflammatory agent. sPLA2 inhibitor prevents deposition of collagen and has anti-fibrotic effects in hypertensive rats.
sPLA2 inhibitor is lipophilic and corresponds to a molecular weight of 487.63 Da. It regulates inflammatory responses and lipoprotein function and may be useful in treating atherosclerosis.
sPLA2 inhibitor (pla2g2a) is an orally active, potent secretory Phospholipase A2 (sPLA2; Group IIa) inhibitor. Secretory phospholipase A2 inhibitor blocks the activation of NF-KB, Akt, p38 MAPK and ERK pathways. sPLA2 inhibitor reduces proliferation and induces apoptosis of lung cancer cells and is a potent anti-inflammatory agent. sPLA2 inhibitor prevents deposition of collagen and has anti-fibrotic effects in hypertensive rats.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maung-Maung Thwin et al.
Arthritis research & therapy, 11(5), R138-R138 (2009-09-22)
Secretory phospholipase A2 (sPLA2) and matrix metalloproteinase (MMP) inhibitors are potent modulators of inflammation with therapeutic potential, but have limited efficacy in rheumatoid arthritis (RA). The objective of this study was to understand the inhibitory mechanism of phospholipase inhibitor from
Robert C Reid
Current medicinal chemistry, 12(25), 3011-3026 (2005-12-28)
Phospholipases A2 cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes that have been proven to exacerbate numerous diseases that have an inflammatory component. Current therapies include NSAIDs' that
Scott Levick et al.
Journal of immunology (Baltimore, Md. : 1950), 176(11), 7000-7007 (2006-05-20)
The development of fibrosis in the chronically hypertensive heart is associated with infiltration of inflammatory cells and cardiac hypertrophy. In this study, an inhibitor of the proinflammatory enzyme, group IIA human secretory phospholipase A2 (sPLA2-IIA), has been found to prevent
Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death
Titsworth WL, et al.
Glia, 57(14), 1521-1537 (2009)
Jessica A Yu et al.
Anticancer research, 32(9), 3601-3607 (2012-09-21)
Group IIa secretory phospholipase A2 (sPLA2 IIa) has been implicated in the regulation of metastasis of non-small cell lung cancer (NSCLC) and the present study investigates its contribution to lung cancer growth and progression. PLA2s initiate signaling in several pathways

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service